MB-105 in Patients With CD5 Positive T-cell Lymphoma
Public ClinicalTrials.gov record NCT06534060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).
Study identification
- NCT ID
- NCT06534060
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- March Biosciences Inc
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Genetic: MB-105 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2025
- Primary completion
- Jan 31, 2028
- Completion
- Nov 30, 2029
- Last update posted
- Oct 2, 2025
2025 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of San Diego (UCSD)-Moores Cancer Center | San Diego | California | 92037 | Recruiting |
| SCRI - Colorado Blood Cancer Institute (CBCI) | Denver | Colorado | 92037 | Not yet recruiting |
| Moffitt Cancer Center Magnolia Campus | Tampa | Florida | 33612 | Recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| University of Nebraska | Omaha | Nebraska | 68198 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Not yet recruiting |
| Oregan Health & Science University | Portland | Oregon | 97239 | Not yet recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06534060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06534060 live on ClinicalTrials.gov.